First trimester extended screening | Rózsakert Medical Center

First trimester extended screening

Our Fetal Medicine Center’s screening protocol extends to 38 exam areas, enabling us to detect 60% of general developmental disorders and 90% of severe heart defects in the first trimester. (With the screening method used, 96-98% of Down syndrome cases can be detected.) Results can be made more precise in the second trimester, because as the fetus grows, further parameters can be examined.  By the end of the 20th week, 90% of developmental disorders and nearly 100% of severe heart defects can be detected.

The first trimester extended screening test is interactive and informative, and lasts an average of 60 minutes.

The screening test includes:

  • Cardiovascular screening
  • Combined-extended Down syndrome screening (according to FMF recommendations: MA, NT, NB, TR, DV, FHR, PAPP-A, β-HCG)*
  • Full anatomical screening (e.g. brainstem, palate, umbilical cord, fingers)
  • Age-based genetic opinion (automatically part of the testing for expectant mothers over 35)
  • Optional supplementary test: determination of the risk of developing pre-eclampsia (toxemia of pregnancy) (according to FMF recommendations: UtA-PI, PAPP-A, PLGF, maternal blood pressure in both arms, medical history)
  • Measurement of expectant mother’s body mass index (BMI)
  • Test for gestational diabetes (GDM), management if necessary

*MA: maternal age, NT: nuchal translucency, NB: nasal bone, TR: tricuspid regurgitation (heart valve exam), DV: ductus venosus (fetal abdominal artery flow exam), FHR: fetal heart rate, PAPP-A, β-HCG: hormones, from blood tests, PLGF: placental growth factor, from blood test, UtA-PI: uterine artery circulation test

More than down syndrome screening

The first trimester extended screening test is the most important pre-natal test. In our center, we give a reliable answer not only to the question of whether the fetus has Down, Edwards, or Patau syndrome, but we look at every disorder that medical science has made it possible to screen for during the 12th week of pregnancy.

 

PREECLAMPSIA SCREENING

Preeclampsia has always been a source of uncertainty during pregnancy. We do not = know when and why it occurs, and to whom, though we can say who is more likely to contract it. Preeclampsia occurs in 2-5% of pregnancies, and if it develops before the 34th week of pregnancy (0.3-0.5%), there can be very serious consequences for both the mother and child. This is why a new medical procedure which has made it possible to determine the likelihood of developing the condition with 90% accuracy is a huge step forward.

What is preeclampsia?

Preeclampsia is sometimes also referred to as toxemia, pregnancy-induced hypertension or preeclamptic toxemia. It can present itself after the 20th week of pregnancy and can affect any expectant mother, usually without any prior warning. Its symptoms include the sudden development of high blood pressure (140/90 mmHg and above) and the presence of protein in the urine. The most important danger with regards to preeclampsia is that it can cause serious and long lasting damage to both the mother and baby. It can lead to kidney and liver failure, stroke or eclampsia for the mother, and lack of growth, oxygen deficiency and complications due to premature labor for the baby. According to the latest research, it is possible to reduce the risks of early developing preeclampsia*.

For any high risk cases identified during the screening process, a solution for prevention of preeclampsia is offered: Taking 150 mg of aspirin daily between the 14th and 36th week of pregnancy can be effective in preventing the development of early preeclampsia, reducing the chances of it occurring by 80%. Interestingly, a predecessor of aspirin, willow bark, was known and applied by the celebrated Greek doctor Hippocrates.

Because of the high risk of developing preeclampsia, the serious potential consequences and the possibility of evidence-based treatment, a test for preeclampsia is now included in our first trimester screening. (The test is not available if the mother is expecting twins, with the necessary FMF database currently under processing.)

* Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia

28 June 2017, The New England Journal of Medicine

Daniel L. Rolnik, M.D., David Wright, Ph.D., Liona C. Poon, M.D., Neil O’Gorman, M.D., Argyro Syngelaki, Ph.D., Catalina de Paco Matallana, M.D., Ranjit Akolekar, M.D., Simona Cicero, M.D., Deepa Janga, M.D., Mandeep Singh, M.D., Francisca S. Molina, M.D., Nicola Persico, M.D., Jacques C. Jani, M.D., Walter Plasencia, M.D., George Papaioannou, M.D., Kinneret Tenenbaum-Gavish, M.D., Hamutal Meiri, Ph.D., Sveinbjorn Gizurarson, Ph.D., Kate Maclagan, Ph.D., and Kypros H. Nicolaides, M.D.

Cranium and central nervous system

  • early developmental disorders of the brain and the bones of the skull (e.g. holoprosencephaly, exencephaly, etc.)

Facial skeleton

  • disorders of the eye and eye sockets
  • hard palate disorders (cleft lip and palate)

Chest, lungs and diaphragm

  • formal deformity of the chest
  • diaphragmatic hernia

Heart

  • formal, situational, size and heart rate abnormalities
  • disorders of the heart chambers and septa dividing the chambers
  • disorders of the major blood vessels (aorta, pulmonary artery) (e.g.TGA transposition of the great arteries, pulmonary artery stenosis/occlusion, abnormalities in the blood vessels of the aortic arch, etc.)
  • abnormal thickening of the heart muscle
  • signs of decompensated fetal circulation (e.g. accumulation of pericardial fluid, pleural fluid, abdominal fluid accumulation)

Abdominal wall defects

  • (e.g. umbilical hernia, abdominal wall hernia)

Gastrointestinal system

  • stomach fluid, stomach position

Urine production and elimination system

  • abnormal renal pelvis dilatation
  • bladder filling rate (megacystis)

Skeleton and limbs

  • spinal disorders (spina bifida, formal deformities)
  • formal abnormalities  of the limbs (e.g. missing limb, deformations of limb bones)

Placenta, umbilical cord, amniotic sac

  • positional disorders of the placenta (placenta previa)
  • disorder of the connection of the placenta to the uterine wall (hematoma)
  • with twin pregnancies, determination of chorionicity and placentation (mono- and dichorionic twin pregnancies)

Screening for abnormalities which increase the risk of chromosomal disorders and heart development defects

  • nuchal fold thickness, absence of nose bone, abnormal ductus venosus flow, abnormal tricuspid valve function

Twin pregnancy

  • developing a complex pre-natal care protocol in monochorionic pregnancies
  • management of twin-to-twin transfusion syndrome (TTTS)
Doctors: 
Elekes Tibor

Dr. Tibor Elekes, M.D.

Monday: 
Tuesday: 
8:00 - 18:00
Wednesday: 
8:00 - 17:30
Thursday: 
Friday: 
8:00 - 12:30
Saturday: 
Csermely Gyula

Dr. Gyula Csermely, M.D., Ph.D.

Monday: 
8:00 - 15:00
Tuesday: 
8:00 - 15:00
Wednesday: 
8:00 - 12:00
Thursday: 
8:00 - 15:00
Friday: 
Saturday: 
Why you shouldn’t undergo a maternal-fetal medicine screening without a test for preeclampsia
2017. September 18.
Preeclampsia (PE) is a dangerous and common condition which can have serious consequences for both the expectant mother and the baby. At its summer congress, the Fetal Medicine Foundation presented...
Why you shouldn’t undergo a maternal-fetal medicine screening without a test for preeclampsia
2017. September 18.
Preeclampsia (PE) is a dangerous and common condition which can have serious consequences for both the expectant mother and the baby. At its summer congress, the Fetal Medicine Foundation presented...